Emerging Views On Emerging Markets: Goldman Sachs Health Care Conference
This article was originally published in PharmAsia News
PharmAsia News takes a closer look at presentations by Abbott, Amgen, Medtronic, Mylan, Shire, Stryker and Valeant.
You may also be interested in...
In the latest of more than a dozen acquisitions Valeant has made since it was created by a merger with Biovail SA in 2011, Valeant’s purchase of Bausch & Lomb will increase its eye care portfolio substantially.
The Montreal pharma company includes a focus on OTCs and generics in its quest to grow while remaining relatively immune to patent cliffs and scaled-back Rx reimbursements. Valeant’s recent PEDiNOL Pharmacal acquisition, including OTC podiatry products, fits into its niche category strategy.
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.